Company: MIRA
Filing Date: 2025-03-28
Form Type: 10-K
Source: 0001641172-25-001183
Chunk: 113

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-03-28
Form: 10-K
Item: Item 1A
Chunk 113
---
 audit to obtain reasonable assurance about whether the financial statements are free of
material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of
its internal control over financial reporting. As part of our audit, we are required to obtain an understanding of internal control over
financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over
financial reporting. Accordingly, we express no such opinion.

Our audit included performing procedures to assess the risks of material
misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures
included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit also included
evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation
of the financial statements. We believe that our audit provides a reasonable basis for our opinion.

We served as the Company’s auditor from 2022 to 2024.

/s/
Cherry Bekaert LLP

Tampa,
Florida

April
1, 2024

F-3

MIRA
PHARMACEUTICALS, INC.

BALANCE
SHEETS

    2024  
    2023 

    December
    31, 

    2024  
    2023 
  
    ASSETS 

    Current
    assets: 

    Cash 
    $2,832,931  
    $4,602,566 
  
    Other
    receivables 
     -  
     11,862 
  
    Prepaid
    expenses 
     54,729  
     243,802 
  
    Total
    current assets 
     2,887,660  
     4,858,230 

    Operating
    lease, right of use assets 
     -  
     5,061 
  
    Related
    party receivable 
     35,439  
     69,152 
  
    Total
    assets 
    $2,923,099  
    $4,932,443 

    LIABILITIES
    AND STOCKHOLDERS’ EQUITY 

    Current
    liabilities: 

    Trade
    accounts payable and accrued liabilities 
    $723,349  
    $538